The DOI matches its Crossref record; the references it cites are not checked yet.
Tumor and Host-Mediated Pathways of Resistance and Disease Progression in Response to Antiangiogenic Therapy
Open accessAbstract
Despite early benefits seen in cancer patients treated with antivascular endothelial growth factor (VEGF) pathway-targeted drugs, the clinical benefits obtained in terms of progression-free or overall survival have been more modest than expected. This outcome is, at least in part, due to antiangiogenic drug resistance mechanisms that involve pathways mediated largely by the tumor, whether intrinsic or acquired in response to therapy, or by the host, which is either responding directly to therapy or indirectly to tumoral cues. The focus of this review is to distinguish, where possible, between such host and tumor-mediated pathways of resistance and discuss key challenges facing the preclinical and clinical development of antiangiogenic agents, including potential differences in drug efficacies when treating primary tumors or various stages of metastatic disease. (Clin Cancer Res 2009;15(16):5020–5)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Drug resistance in cancer can be cell-intrinsic or a combination of host and tumor mediated pathways.
“Drug resistance in cancer can be cell-intrinsic (Poulikakos and Rosen, 2011) or a combination of host and tumor mediated pathways (Bergers and Hanahan, 2008; Ebos et al., 2009).”
From A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis (2012) · cites this paper as Ebos et al., 2009
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists haven’t been fetched yet
References 88 · Cited by 291
Metadata
- Authors
- Ebos, J. M. L., Lee, C. R., & Kerbel, R. S.
- Affiliations
- Sunnybrook Health Science Centre (CA)
- Corresponding author
- Kerbel, Robert S.
- Venue
- Clinical Cancer Research
- Published
- 2009-08-12
- Volume
- 15
- Issue
- 16
- Pages
- 5020-5025
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- PMC
- PMC2743513
- OpenAlex
- W2151637779
- Cited by
- 291
- References
- 88
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 7 · 2023: 10 · 2022: 5 · 2021: 13 · 2020: 10 · 2019: 17 · 2018: 13 · 2017: 15 · 2016: 15 · 2015: 24 · 2014: 29 · 2013: 28 · 2012: 26
- FWCI
- 2.44
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA041233)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- anti-angiogenic therapy, drug resistance, VEGF pathway, tumor angiogenesis, disease progression, metastatic disease, primary tumor
- MeSH terms
- Humans, Models, Biological, Neoplasms, Signal Transduction, Disease Progression, Drug Resistance, Neoplasm, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
